Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV
Clinical Pharmacology & Therapeutics · 2024-06 · 115 (6) · 1450-1459
DOI: 10.1002/cpt.3240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 22.03.2024. Verfasst von Paul Thoueille und 24 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausan…. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Models, Biological. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Long‐acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings. The present population pharmacokinetic analysis aims to build real‐world reference percentile curves of cabotegravir concentrations, accounting for patient‐related factors that may affect cabotegravir exposure. The second objective is to simulate whether dosing interval adjustments of cabotegravir could be considered in specific subpopulations. Overall, 238 PWH contributed to 1,038 cabotegravir levels (186 during the initial oral administration phase and 852 after intramuscular injection). Cabotegravir pharmacokinetics was best described using a one‐compartment model with distinct first order‐absorption for oral and intramuscular administrations, and identical volume and clearance. Our model showed almost 40% faster absorption and 30% higher clearance than previously reported, resulting in a time to steady‐state of 8 months and an elimination half‐life of 4.6 weeks for long‐acting cabotegravir. Sex and body mass index significantly influenced absorption, and bodyweight affected clearance. Model‐based simulations showed that cabotegravir trough concentrations in females were 25% lower 4 weeks after the intramuscular loading dose, but 42% higher during the late maintenance phase. Finally, simulations indicated that in females, despite significantly higher cabotegravir concentrations, longer intervals between injections may not consistently ensure levels above the 4‐fold protein‐adjusted 90% inhibitory target concentration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Service of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
- Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
- Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
ORCID-Profile: Paul Thoueille, Eva Choong, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F Günthard, Jessy J Duran Ramirez, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Enos Bernasconi, Catia Marzolini, François R Girardin, Thierry Buclin, Laurent A Decosterd, Monia Guidi
Zitieren
APA
Thoueille, P., Saldanha, S. A., Schaller, F., Choong, E., Veuve, F., Munting, A., Cavassini, M., Braun, D., Günthard, H. F., Duran Ramirez, J. J., Surial, B., Furrer, H., Rauch, A., Ustero, P., Calmy, A., Stöckle, M., Di Benedetto, C., Bernasconi, E., Schmid, P., …, & Swiss HIV Cohort Study (2024). Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV. Clinical Pharmacology & Therapeutics, 115(6), 1450-1459. https://doi.org/10.1002/cpt.3240
Vancouver
Thoueille P, Saldanha SA, Schaller F, Choong E, Veuve F, Munting A, et al. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV. Clinical Pharmacology & Therapeutics. 2024;115(6):1450-1459. doi:10.1002/cpt.3240
BibTeX
@article{Thoueille2024,
author = {Thoueille, Paul and Saldanha, Susana Alves and Schaller, Fabian and Choong, Eva and Veuve, François and Munting, Aline and Cavassini, Matthias and Braun, Dominique and Günthard, Huldrych F and Duran Ramirez, Jessy J and Surial, Bernard and Furrer, Hansjakob and Rauch, Andri and Ustero, Pilar and Calmy, Alexandra and Stöckle, Marcel and Di Benedetto, Caroline and Bernasconi, Enos and Schmid, Patrick and Marzolini, Catia and Girardin, François R and Buclin, Thierry and Decosterd, Laurent A and Guidi, Monia and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
title = {Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {115},
number = {6},
pages = {1450--1459},
doi = {10.1002/cpt.3240}
}
EUVIMED